drugset / Trial / NCT03022123
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
270 untreated patients, age between 18 and 65 years , with diffuse large B-cell lymphoma (B-DLCL) were treated with a pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rituximab regimen. PL-doxorubicin 35-40 mg/m(2)and epirubicin 70mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
Timeline
- Start
- 2016-11
- Primary completion
- 2017-11
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Subject | Epirubicin | Small molecule | 70 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Granulocyte colony-stimulating factor | Protein / enzyme biologic | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | — | — |